Clinical and subclinical intestinal inflammation assessed by the mucosal patch technique: studies of mucosal neutrophil and eosinophil activation in inflammatory bowel diseases and irritable bowel syndrome.
about
Diagnosis and management of functional symptoms in inflammatory bowel disease in remissionConcepts of oxidative stress and antioxidant defense in Crohn's diseaseGluten sensitivity in patients with primary Sjögren's syndromeMeasurements of eosinophil activation before and after food challenges in adults with food hypersensitivity.A spontaneous animal model of intestinal dysmotility evoked by inflammatory nitrergic dysfunction.Butyric acid in functional constipation.From intestinal permeability to dysmotility: the biobreeding rat as a model for functional gastrointestinal disordersAnalysing the eosinophil cationic protein--a clue to the function of the eosinophil granulocyte.Roles of the host oxidative immune response and bacterial antioxidant rubrerythrin during Porphyromonas gingivalis infection.What does irritable bowel syndrome share with non-alcoholic fatty liver disease?Immunological alteration and changes of gut microbiota after dextran sulfate sodium (DSS) administration in mice.Lessons Learnt from Post-Infectious IBS.Effects of Hypericum perforatum extract on rat irritable bowel syndrome.Gut mucosal granulocyte activation precedes nitric oxide production: studies in coeliac patients challenged with gluten and corn.Posttranslationally modified proteins as mediators of sustained intestinal inflammation.Fecal Myeloperoxidase as a Biomarker for Inflammatory Bowel Disease.Cow's milk protein sensitivity assessed by the mucosal patch technique is related to irritable bowel syndrome in patients with primary Sjögren's syndromeCD14+CD33+ myeloid cell-CCL11-eosinophil signature in ulcerative colitis.An Orally Active Cannabis Extract with High Content in Cannabidiol attenuates Chemically-induced Intestinal Inflammation and Hypermotility in the Mouse.Diagnostic utility of faecal biomarkers in patients with irritable bowel syndromeImmune activation in irritable bowel syndrome: can neuroimmune interactions explain symptoms?Reduction of experimental colitis in the rat by inhibitors of glycogen synthase kinase-3beta.Subclinical mucosal inflammation in diarrhea-predominant irritable bowel syndrome (IBS) in a tropical setting.Effects of probiotic fermented milk on symptoms and intestinal flora in patients with irritable bowel syndrome: a randomized, placebo-controlled trial.Inhibition of corticotropin-releasing hormone receptor 1 and activation of receptor 2 protect against colonic injury and promote epithelium repair.The role of polymorphonuclear neutrophils during HIV-1 infection.Hemorrhagic shock induces a proinflammatory milieu in the gut lumenAttenuation of inflammation and cytokine production in rat colitis by a novel selective inhibitor of leukotriene A4 hydrolase.Severe eosinophilic infiltration in colonic biopsies predicts patients with ulcerative colitis not responding to medical therapy.Abdominal pain and the neurotrophic system in ulcerative colitis.Detection of inflammatory markers in stools from patients with irritable bowel syndrome and collagenous colitis.Serum metabolic profiling in inflammatory bowel disease.Current insights into the innate immune system dysfunction in irritable bowel syndrome.Visceral abdominal obesity is associated with an increased risk of irritable bowel syndrome.Evaluation of biomarkers for ulcerative colitis comparing two sampling methods: fecal markers reflect colorectal inflammation both macroscopically and on a cellular level.Transplantation of human umbilical mesenchymal stem cells attenuates dextran sulfate sodium-induced colitis in mice.Quantitative Analysis of Distribution of the Gastrointestinal Tract Eosinophils in Childhood Functional Abdominal Pain Disorders
P2860
Q26768264-11CDCEC7-91E7-4BAA-A067-95D01526762DQ26827460-308399CA-8BA7-44B3-87A1-FCC41477408CQ28235449-E0BD8579-3779-4B31-9CAF-BEADB2251E6FQ33435371-476DC717-3C8B-4BC6-8C2D-EA638606101AQ33599727-5EBB8E58-D51E-46D0-8C5D-E3FE0E163184Q33636641-B8F3B259-D2AE-45AB-B22D-6847227302D0Q34420883-0CDBE6D2-1C67-415A-BBE3-2C6F77325216Q34537757-BA42D0EF-B492-4749-A603-64BBD8021519Q34862986-35FD71CB-DE57-4741-9728-EE20C165C914Q34983471-C38F5DCF-D3C7-4399-B297-089D61D74980Q35020376-006FBA39-CB5C-43C9-8877-B0B488150A69Q35176122-4AC7A6E5-3A06-4A37-A7FA-BFB4EF27236CQ35215213-55919F33-2DE9-49AE-A27C-10B6E9A3802AQ35597438-BFCFB652-3DED-4678-9032-94A67B1EAF73Q35607249-BAAC1572-9973-4356-9F41-390ADA158FE2Q36305774-C02C7AF2-2750-4E8A-B83B-700762695DD6Q36736910-32D13429-85E2-4E17-B7C5-F8123E12D3C4Q37238312-FA1648C2-1D42-46FD-AEB2-4405B770E37EQ37306421-030190AD-8C51-4E4F-BD8F-CCDF34FF06BEQ37581340-61582870-541E-4FFE-8A71-7942E9A64277Q38104610-FFB731AA-4EE3-4921-BF62-A442613B04FBQ38756671-5C1FCA39-7BF8-41D5-A9AB-178D87902D12Q38967008-07D2B50B-0047-4A60-8282-041F04BA508CQ39268498-2B771D6F-4D1E-45D3-BC43-4C9AD8A3A1B2Q41901925-45817542-6507-4018-9E58-29FD93D40E1FQ41923884-FED6F53E-5560-47EE-88E5-21C156DDDA81Q42145796-E27CB594-A1DB-4906-9371-21F3D222429EQ43075788-F6C746D3-8154-464C-AE9D-5A2048ADE837Q44658531-30F14009-8D51-4FE9-A491-33187433F760Q45127551-329A3541-669A-4370-AADC-CB8C31B279B3Q46864466-ED3BF046-5143-4DBB-841E-980519986127Q49162097-5F65A36B-DC52-4283-B5B2-A52D66042CDFQ52673108-34645127-9281-4180-BAFD-8A51CB66AAE9Q53031023-02379D42-228A-42E5-A5E5-909E6706C94EQ53094752-6517C3C8-85D0-436D-8B43-06BB6602E0C7Q54401840-D72DBF82-2B9A-428E-B594-3E135807A421Q57098677-82B2FC5B-43A9-42B7-8990-D194AD640B1B
P2860
Clinical and subclinical intestinal inflammation assessed by the mucosal patch technique: studies of mucosal neutrophil and eosinophil activation in inflammatory bowel diseases and irritable bowel syndrome.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Clinical and subclinical intes ...... and irritable bowel syndrome.
@ast
Clinical and subclinical intes ...... and irritable bowel syndrome.
@en
type
label
Clinical and subclinical intes ...... and irritable bowel syndrome.
@ast
Clinical and subclinical intes ...... and irritable bowel syndrome.
@en
prefLabel
Clinical and subclinical intes ...... and irritable bowel syndrome.
@ast
Clinical and subclinical intes ...... and irritable bowel syndrome.
@en
P2093
P2860
P356
P1433
P1476
Clinical and subclinical intes ...... and irritable bowel syndrome.
@en
P2093
P2860
P304
P356
10.1136/GUT.2003.036418
P407
P577
2004-12-01T00:00:00Z